Mechanism of action of didemnin B, a depsipeptide from the sea
- PMID: 6744252
- DOI: 10.1016/0304-3835(84)90095-8
Mechanism of action of didemnin B, a depsipeptide from the sea
Abstract
With the brush border membrane vesicles prepared from the rat kidney cortex, didemnin B and its parent compound, didemnin A function neither as a K+-specific ionophore nor as an ionophore for Na+ ions while other depsipeptide antibiotics such as valinomycin and gramicidin promote transmembrane movement of K+ and Na+ ions, respectively. Didemnin B inhibits protein synthesis and DNA synthesis much more than RNA synthesis and is in general more potent than didemnin A. Time course studies reveal that the action of didemnin B is rapid and cannot be reversed after 2 h in contact with the cells. The inhibition of protein synthesis is almost superimposable to that of L1210 cells growth. DNA synthesis is also markedly inhibited. These results collectively suggest that didemnin B acts differently, at least in part, from other depsipeptide antibiotics and its biological effect is primarily mediated through its inhibition of protein synthesis and to a lesser extent its inhibition of DNA synthesis.
Similar articles
-
Biochemical and cellular effects of didemnins A and B.Cancer Res. 1984 May;44(5):1796-801. Cancer Res. 1984. PMID: 6713383
-
Sulphate-ion/sodium-ion co-transport by brush-border membrane vesicles isolated from rat kidney cortex.Biochem J. 1979 Jul 15;182(1):223-9. doi: 10.1042/bj1820223. Biochem J. 1979. PMID: 91368 Free PMC article.
-
Didemnin B. The first marine compound entering clinical trials as an antineoplastic agent.Invest New Drugs. 1986;4(3):279-84. doi: 10.1007/BF00179597. Invest New Drugs. 1986. PMID: 3546184 Review.
-
Mechanism of protein synthesis inhibition by didemnin B in vitro.Biochemistry. 1995 Jul 18;34(28):9177-84. doi: 10.1021/bi00028a030. Biochemistry. 1995. PMID: 7619818
-
Natural products as probes of cell biology: 20 years of didemnin research.Med Res Rev. 2002 Mar;22(2):102-45. doi: 10.1002/med.10003. Med Res Rev. 2002. PMID: 11857636 Review.
Cited by
-
Synthetic and Naturally Occurring Heterocyclic Anticancer Compounds with Multiple Biological Targets.Molecules. 2021 Nov 25;26(23):7134. doi: 10.3390/molecules26237134. Molecules. 2021. PMID: 34885716 Free PMC article. Review.
-
Crystal and molecular structure of didemnin B, an antiviral and cytotoxic depsipeptide.Proc Natl Acad Sci U S A. 1988 Jun;85(12):4118-22. doi: 10.1073/pnas.85.12.4118. Proc Natl Acad Sci U S A. 1988. PMID: 3380783 Free PMC article.
-
Accumulation of HL-60 leukemia cells in G2/M and inhibition of cytokinesis caused by two marine compounds, bistratene A and cycloxazoline.Cancer Chemother Pharmacol. 1994;33(5):399-409. doi: 10.1007/BF00686269. Cancer Chemother Pharmacol. 1994. PMID: 8306414
-
Anticancer activity of pyrimidodiazepines based on 2-chloro-4-anilinoquinazoline: synthesis, DNA binding and molecular docking.RSC Adv. 2021 Jul 1;11(38):23310-23329. doi: 10.1039/d1ra03509f. eCollection 2021 Jul 1. RSC Adv. 2021. PMID: 35479808 Free PMC article.
-
Phase I clinical study of didemnin B. A National Cancer Institute of Canada Clinical Trials Group study.Invest New Drugs. 1998;16(1):51-6. doi: 10.1023/a:1006099401417. Invest New Drugs. 1998. PMID: 9740544 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
